Normal & Target Blood Pressure at Age 75

What "Normal" Means at 75

• Arteries naturally stiffen with age, causing systolic (top number) to rise while diastolic (bottom number) may fall or stay the same.
• Up to 80% of women and a high proportion of men over age 75 have hypertension, making some degree of elevation very common - but "common" does not mean "safe."

BP Classification (applies to all adults including age 75)

Treatment Targets for Age 75 - What Major Guidelines Say

Key Practical Points for a 75-Year-Old

1. Ideal target: < 130/80 mmHg if the person is functionally independent, ambulatory, and tolerates medication well.
2. < 140/90 mmHg is an acceptable target for frail older adults, those with multiple comorbidities, or those prone to falls/dizziness.
3. Diastolic pressure (bottom number) should not go too low - keeping DBP above 60-70 mmHg is important at this age, as very low diastolic pressure can reduce coronary perfusion.
4. The SPRINT trial showed that targeting SBP < 120 mmHg cut fatal/nonfatal cardiovascular events by 25-34%, but came with a small increase in adverse effects like hypotension, syncope, and acute kidney injury - especially relevant for older adults.
5. Frailty matters - for frail elderly or nursing home residents, overly aggressive BP lowering can cause falls and dizziness. A slightly higher target (< 150/80 mmHg) may be safer in that group (as used in the HYVET trial for patients over 80).

Bottom Line

• Fuster and Hurst's The Heart, 15th Ed., Hypertension section
• National Kidney Foundation Primer on Kidney Diseases, 8e, Older Adults with CKD section

Recent Guidelines on Hypertension Management in Frail Elderly (2023-2025)

1. The Core Principle: Frailty Assessment First

• Fried Frailty Phenotype (weight loss, exhaustion, weakness, slow gait, low activity)
• Comprehensive Geriatric Assessment (CGA)
• 4Ms Framework - Mentation, Medications, Mobility, and "What Matters Most"

2. BP Targets by Guideline and Frailty Category

Summary Table

3. The ALARA Principle (2024 ESC) - Key Concept

• Drug treatment threshold: ≥ 140/90 mmHg (Class IIa, Level B)
• Target: "As Low As Reasonably Achievable" - lenient goals (< 140/90 mmHg) to prioritize tolerability (Class IIa/IIb, Level C)
• Supported by the HYVET trial (patients ≥80 years: targeting SBP < 150 mmHg was safe, reduced stroke and mortality)

4. Landmark Trial Evidence Informing These Guidelines

5. Pharmacological Guidance for Frail Elderly

Preferred Drug Classes

• Thiazide-like diuretics (indapamide, chlorthalidone) - first line, evidence from HYVET
• ACE inhibitors / ARBs - beneficial especially with CKD or heart failure comorbidity
• Long-acting dihydropyridine CCBs (amlodipine) - good tolerability in elderly
• Stepped-care approach is recommended over single-pill combination (SPC) in older adults (2025 ACC/AHA)

Drugs to Use with Caution

• Alpha-blockers - increased orthostatic hypotension risk (2025 ACC/AHA caution)
• Short-acting dihydropyridines - risk of reflex tachycardia
• High-dose diuretics - dehydration, electrolyte imbalance risk

Non-pharmacological (equally important in frail elderly)

• Salt restriction (< 3 g/day) - effective and reduces polypharmacy burden
• Aerobic exercise - Class I recommendation in 2025 ACC/AHA even for elderly
• Plant-dominant / DASH diet
• Avoiding dehydration - frail elderly often have reduced thirst sensation

6. Special Considerations Unique to Frail Elderly

Orthostatic Hypotension

• Must be screened before and during treatment
• BP should be measured lying, sitting, and standing
• If SBP drops > 20 mmHg or DBP drops > 10 mmHg on standing, aggressive targets are contraindicated

Deprescribing

• Actively recommended when SBP < 130 mmHg in frail patients on multiple antihypertensives
• The OPTIMISE trial showed safe deprescribing down to ~SBP 150 mmHg in patients ≥80 years
• The "STOPP/START" criteria include guidance on deprescribing antihypertensives in frail elderly

Dementia Prevention

• New in 2025 ACC/AHA: Class I recommendation that SBP < 130 mmHg reduces risk of mild cognitive impairment (MCI) and dementia - applies even in older adults

Shared Decision-Making

• Both ACC/AHA 2025 and ESC 2024 emphasize discussing patient goals, life expectancy, and values before setting targets
• For the oldest-old, "what matters most" should drive the target, not a number alone

7. Practical Decision Framework

Step 1: Assess frailty (CFS score)
    CFS 1-5 (robust/mild frailty) → Target < 130/80 mmHg
    CFS 6-7 (moderate frailty, IADL impaired) → Target < 140 mmHg
    CFS 8-9 (severe frailty / ADL-dependent) → Target < 150 mmHg; consider deprescribing

Step 2: Screen for orthostatic hypotension
    If present → use ALARA principle, prioritize tolerability

Step 3: Choose drug therapy
    Start low, go slow; stepped-care preferred
    Avoid alpha-blockers; caution with high-dose diuretics

Step 4: Monitor for adverse effects
    Falls, dizziness, AKI, electrolyte disturbance, fatigue

Step 5: Reassess regularly
    Frailty status changes; BP targets should change with it

• 2024 ESC Hypertension Guidelines (McEvoy et al., PMID: 39210715)
• 2025 ACC/AHA Guideline narrative comparison
• JSH 2025 older adults comparison
• Hu et al. 2023 systematic review of 13 guidelines (PMID: 37594718)
• Choi et al. 2025 frail older adults management review

Clinical Trial Evidence: Orthostatic Hypotension Risk in Frail Elderly BP Management

What the Evidence Actually Shows (and Why It's Surprising)

Key Trials and Meta-Analyses

1. Juraschek et al., BMJ 2025 - Individual Participant Data Meta-Analysis

• At baseline, 9% of patients had OH and 17% had orthostatic hypertension (BP rising on standing)
• More intensive BP treatment actually reduced orthostatic hypertension (OR 0.93, 95% CI 0.90-0.96)
• Effects did not differ by age ≥75 years - meaning intensive treatment was not more likely to cause OH in older adults
• Subgroup interactions: slightly attenuated benefit in Black adults and those with diabetes

Bottom line: Intensive antihypertensive treatment modestly reduces orthostatic hypertension and does not significantly increase OH across age groups.

2. Klop et al., Experimental Gerontology 2024 - Systematic Review & Meta-Analysis

• Initiating or augmenting antihypertensive therapy → OH prevalence decreased (RR 0.39, 95% CI 0.21-0.72)
• Discontinuing antihypertensives → OH prevalence also decreased (RR 0.39, 95% CI 0.28-0.55)
• Actual postural BP drop (mmHg change) did not significantly change after starting/increasing AHT (mean difference 1.07, p=0.18)
• Most included studies reported OH incidence of 0-2% when standardized measurement was used

Key message: Clinician worry about causing OH by starting antihypertensives in older adults may be overestimated. The risk of OH is real but does not rise linearly with treatment initiation.

3. Reddin et al., Age & Ageing 2023 - Systematic Review of 46 RCTs

• Antihypertensive therapy was not associated with increased fall risk whether patients with OH were excluded (OR 1.00) or included (OR 1.02)
• Hypotension incidence was lower in trials that excluded OH patients (1.3% vs 6.2%, p<0.001), but fall and syncope rates did not differ significantly between exclusion groups
• P for interaction = 0.90 (no difference in treatment effect based on OH status)

Clinical implication: Trials that exclude patients with pre-existing OH do not produce inflated safety signals - meaning the field's exclusion of these patients may be obscuring a treatable population.

4. BedMed-Frail RCT, JAMA Network Open 2025 - Timing of Antihypertensives in Frail Elderly

• Population: 85.6% had dementia, 47.3% diabetes, median age 88 years - genuinely frail
• No difference in composite death/MACE outcome (aHR 0.88, p=0.28)
• No difference in hypotensive or ischemic adverse events between bedtime and morning groups
• Bedtime dosing did reduce unplanned hospitalizations/ED visits (aHR 0.74, p=0.02) - a secondary finding

Verdict: Medication timing does not meaningfully affect OH risk in frail nursing home residents; this popular clinical workaround has limited evidence.

5. Bhanu et al., PLoS Medicine 2021 - Drug-Induced OH by Drug Class

• Alpha-blockers and vasodilators carry the highest OH risk
• ACE inhibitors, ARBs, and thiazide diuretics had comparatively modest OH signals
• CCBs had intermediate risk
• Antipsychotics and tricyclic antidepressants (common in frail elderly) contributed significantly to drug-induced OH - often underappreciated alongside antihypertensives

6. SPRINT-Senior (Subgroup of SPRINT) - Reference Standard

• Syncope was more frequent in the intensive group (2.3% vs 1.7%)
• Serious hypotension was more frequent (2.4% vs 1.4%)
• BUT: falls and injurious falls were not significantly increased
• Net cardiovascular benefit was preserved even in participants classified as frail

Summary Table: What the Evidence Shows

Clinical Takeaways

1. The fear of OH should not be a barrier to starting antihypertensives in older adults - trial data suggest this risk is overestimated and may be bidirectional.
2. Screen for OH before and after initiating therapy using standardized standing BP measurement (lie-to-stand or sit-to-stand at 1 and 3 minutes).
3. Avoid alpha-blockers and vasodilators as first-line agents in frail elderly - these carry the highest drug-induced OH risk.
4. Bedtime vs. morning dosing does not resolve OH concerns in very frail patients.
5. Falls risk in antihypertensive trials is not increased even when OH-prone patients are included - the OH-to-fall causal chain is not as direct as assumed.
6. In genuinely frail patients with SBP < 130 mmHg on multiple drugs, deprescribing evidence (OPTIMISE trial) supports stepping down to reduce polypharmacy burden while keeping SBP ≤ 150 mmHg.

RCT Evidence: Drug Class Comparisons for Orthostatic Hypotension in Elderly Patients

The Evidence Landscape

1. Large multi-arm RCTs with OH/falls as pre-specified secondary outcomes (ALLHAT)
2. Systematic reviews and meta-analyses pooling placebo-controlled RCTs by drug class (Bhanu et al.)
3. Cochrane reviews comparing drug classes on cardiovascular outcomes with OH as a safety signal

Study 1: ALLHAT Trial - The Only Major Head-to-Head RCT with OH as an Endpoint

Key Findings

Key message: Amlodipine (CCB) showed a significant early (Year 1) increase in falls compared to chlorthalidone and lisinopril - but this equalized by long-term follow-up. Thiazide diuretics and ACE inhibitors appear safer in the first year of treatment in older adults.

Study 2: Bhanu et al. PLoS Medicine 2021 - The Definitive Drug-Class OH Meta-Analysis

OH Risk by Drug Class (ranked highest to lowest risk)

Fundamental insight: The mechanism of OH risk follows a clear pattern - drugs that inhibit sympathetic activity (beta-blockers, alpha-blockers, centrally acting agents) cause the most OH. Drugs that cause vasodilation only (CCBs, ACE-i/ARBs) do not significantly increase OH versus placebo. Cumulative polypharmacy risk rises sharply when two or more sympatho-inhibitory drugs are combined.

Study 3: Cochrane Review - CCBs vs. Other Classes

OH implication: CCBs are superior to beta-blockers for stroke prevention AND carry lower OH risk; but for CHF risk and overall CV event prevention, thiazide diuretics remain first-line in older adults.

Study 4: Klop et al. 2024 - Does Changing AHT Affect OH? (Meta-Analysis in ≥65 yrs)

• Across all drug classes combined, starting or increasing AHT reduced OH prevalence (RR 0.39)
• Stopping AHT also reduced OH prevalence (RR 0.39)
• No drug-class-specific breakdown was possible due to study heterogeneity
• Highlights that OH is a dynamic state - not simply caused by antihypertensives

Synthesis: Drug Class Ranking for OH Safety in Frail Elderly

LOWEST OH RISK (preferred in frail elderly)
  ✅ ACE inhibitors / ARBs      — no significant OH signal vs. placebo
  ✅ Thiazide-like diuretics    — no significant OH signal; best CV event reduction
  ⚠️ CCBs (dihydropyridines)   — no significant OH vs. placebo, but early fall risk in Year 1

INTERMEDIATE OH RISK (use with caution)
  ⚠️ SGLT-2 inhibitors         — volume depletion mechanism; monitor closely
  ⚠️ Non-dihydropyridine CCBs  — cardioinhibitory effects add modest risk

HIGHEST OH RISK (avoid or minimize in frail elderly)
  ❌ Beta-blockers              — OR 7.76 vs. placebo; avoid as first-line in frail
  ❌ Alpha-blockers             — ~2-fold OH risk; STOPP criteria flag these
  ❌ Centrally-acting agents    — avoid (methyldopa, clonidine, moxonidine)
  ❌ Tricyclic antidepressants  — OR 6.30; often co-prescribed unknowingly

Clinical Takeaways from the Trial Evidence

1. Thiazide-like diuretics (indapamide, chlorthalidone) are the safest first-line agents for frail elderly from an OH standpoint - supported by both ALLHAT and HYVET data.
2. ACE inhibitors and ARBs carry no statistically significant OH risk vs. placebo across 8 RCTs (Bhanu et al.).
3. Beta-blockers should be avoided as first-line hypertension agents in frail elderly unless there is a compelling cardiac indication (heart failure with reduced EF, post-MI) - their OH risk is 7-8x that of placebo.
4. Amlodipine requires closer monitoring in the first year - the ALLHAT data show a significant early fall signal that resolves over time, but initial titration in frail patients needs care.
5. Polypharmacy is the dominant OH risk - the combination of a beta-blocker + antipsychotic + antihypertensive in a frail elderly patient carries cumulative OH risk far exceeding any single agent.
6. No RCT has been designed specifically for OH prevention as a primary endpoint in frail elderly - this remains a recognized evidence gap flagged by Hu et al.'s 2023 guideline review.